ArticleInternational journal of peptide research and therapeutics2021
Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches.
Article in International journal of peptide research and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Development of an epitope-based vaccine fromToxicology research · 2025Article
- In silico design and assessment of a multiepitope and multiantigen potential vaccine candidate againstIn silico pharmacology · 2025Article
- Article
- Development of a multi-epitope vaccine candidate for leishmanial parasites applying immunoinformatics andFrontiers in immunology · 2023Article
- Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus.Frontiers in immunology · 2023Article
- In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani.BMC bioinformatics · 2022Article
- Exploratory Algorithm of a Multi-epitope-based Subunit Vaccine Candidate AgainstInternational journal of peptide research and therapeutics · 2022Article
- Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis.International journal of peptide research and therapeutics · 2022Article
- Article
- Response Comment on "A New Immunogenic Structure of Polyepitopic Fusion againstIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is caused by an obligate intracellular protozoan parasite. The clinical forms of leishmaniasis differ from cutaneous leishmaniasis, mucocutaneous leishmaniasis and visceral leishmaniasis (VL) which depend on the parasite species and the host's immune responses. There are significant challenges to the available anti-leishmanial drug therapy, particularly in severe forms of disease, and the rise of drug resistance has made it more difficult. Currently, no licensed vaccines have been introduced to the market for the control and elimination of VL. A potential target for use in candidate vaccines against leishmaniasis has been shown to be
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.